Ledifos

Ledifos generic harvoni recently launched in india. On october 10, 2014, the fixed-dose combination ledipasvir-sofosbuvir (harvoni) was approved by the fda for the treatment of chronic hepatitis c genotype 1 infection in adults. On november 12, 2015 the fda expanded the approval of ledipasvir-sofosbuvir to include (a) treatment of chronic hepatitis c genotypes 4, 5, and 6 and (b) patients coinfected with hiv.